Tema Oncology ETF Rating $44.28 +0.12 (+0.27%) As of 02:33 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort Interest Tema Oncology ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.CANC Aggregate RatingModerate Buy 2.74Holdings in CANC have an aggregate rating of Moderate Buy based on 401 analyst ratings issued in the past year covering 23 companies (70.6% of the portfolio).CANC Aggregate Price Target$44.340.13% UpsideHigh Prediction$44.34Average Prediction$44.34Low Prediction$44.34Holdings in CANC have an aggregate price target of $44.34 and a range of $44.34 to $44.34 covering 23 companies (70.6% of the portfolio).CANC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy1 Buy rating(s)Moderate Buy18 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Oncology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 23 CANC Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings6.29%RVMDRevolution Medicines$210.59+0.7%2.5081 of 5 stars2.95$200.74 -4.7%22Analyst ForecastInsider TradeAnalyst Revision5.48%LLYEli Lilly and Company$1,158.09-0.2%4.9278 of 5 stars2.83$1,292.18 11.6%30Trending NewsAnalyst Upgrade4.84%COGTCogent Biosciences$34.96+1.1%2.4781 of 5 stars2.75$51.56 47.5%12Positive News4.38%RHHBYRoche$55.42+3.0%3.9721 of 5 stars2.45$60.00 8.3%11Analyst RevisionGap Up3.57%MRKMerck & Co., Inc.$152.07+0.3%4.536 of 5 stars2.65$147.60 -2.9%23Positive NewsAnalyst Revision3.56%ABBVAbbVie$260.96-0.3%4.5123 of 5 stars2.88$275.95 5.7%26Trending NewsAnalyst Revision3.52%BMYBristol Myers Squibb$67.89+0.3%4.7187 of 5 stars2.56$66.06 -2.7%25Positive NewsAnalyst Revision3.20%ONCBeOne Medicines$361.94+0.0%3.7827 of 5 stars3.00$402.14 11.1%173.10%JNJJohnson & Johnson$278.02+1.0%4.5663 of 5 stars2.80$272.83 -1.9%25Trending NewsAnalyst ForecastAnalyst Revision3.06%HALOHalozyme Therapeutics$110.26+0.5%3.8114 of 5 stars2.62$91.20 -17.3%13Trending NewsAnalyst UpgradeAnalyst Revision2.94%IMNMImmunome$26.89-1.6%3.0732 of 5 stars2.85$34.64 28.8%13Positive News2.84%AMGNAmgen$443.77+0.2%4.2095 of 5 stars2.40$380.43 -14.3%30Positive NewsAnalyst Revision2.79%CGONCG Oncology$74.03-0.8%3.0705 of 5 stars2.77$83.18 12.4%13Positive News2.77%GMABGenmab A/S$34.20-0.1%3.8345 of 5 stars2.85$39.50 15.5%13Analyst Upgrade2.51%IDYAIDEAYA Biosciences$39.71-1.1%2.847 of 5 stars2.83$50.19 26.4%18Positive NewsAnalyst Forecast2.47%EXELExelixis$59.51+1.7%2.8976 of 5 stars2.35$50.07 -15.9%20Analyst Upgrade2.08%ELVNEnliven Therapeutics$59.44+0.7%2.8686 of 5 stars2.78$75.00 26.2%9Positive News2.02%ZLABZai Lab$27.06+2.2%2.6059 of 5 stars2.71$37.25 37.7%71.93%LEGNLegend Biotech$21.74-0.7%3.1978 of 5 stars2.47$52.29 140.5%15Analyst Upgrade1.86%BBIOBridgeBio Pharma$75.41-1.4%3.417 of 5 stars2.83$101.53 34.6%23Positive NewsAnalyst Forecast1.79%CELCCelcuity$94.98-1.3%2.7839 of 5 stars2.82$154.55 62.7%11Positive NewsAnalyst Forecast1.79%ERASErasca$16.13-1.5%2.1325 of 5 stars2.64$22.09 37.0%11Positive News1.78%RLAYRelay Therapeutics$18.65+0.8%2.9334 of 5 stars2.93$25.92 39.0%14Positive News This page (NASDAQ:CANC) was last updated on 9/3/2026 by MarketBeat.com Staff. From Our PartnersSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Oncology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Oncology ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
